[
  {
    "ts": null,
    "headline": "Vertex: Q4 Earnings Snapshot",
    "summary": "The Boston-based company said it had profit of $4.65 per share. Earnings, adjusted for one-time gains and costs, came to $5.03 per share. The results fell short of Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=3086f67f0fe46a2ab4965a4c8e69fb549947e3b805693db471018b7e52dc3948",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770931040,
      "headline": "Vertex: Q4 Earnings Snapshot",
      "id": 139074861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Boston-based company said it had profit of $4.65 per share. Earnings, adjusted for one-time gains and costs, came to $5.03 per share. The results fell short of Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=3086f67f0fe46a2ab4965a4c8e69fb549947e3b805693db471018b7e52dc3948"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=824733167c952db859db9ad4f442740a84dd51d5b7e8fb958ca48f653d61d2fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770930685,
      "headline": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue",
      "id": 139074862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=824733167c952db859db9ad4f442740a84dd51d5b7e8fb958ca48f653d61d2fc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Reports Fourth Quarter and Full Year 2025 Financial Results",
    "summary": "BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.",
    "url": "https://finnhub.io/api/news?id=4fc14f71eaad8b6a2e8c513d6ffbc5ffecf6068c398ad34fa01c7b8d697704cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770930060,
      "headline": "Vertex Reports Fourth Quarter and Full Year 2025 Financial Results",
      "id": 139074863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.",
      "url": "https://finnhub.io/api/news?id=4fc14f71eaad8b6a2e8c513d6ffbc5ffecf6068c398ad34fa01c7b8d697704cb"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Scheduled For February 12, 2026",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=4fd3756cb1814eaf3610e5b762de807b1939a478aa9530d3d91c54b5f01eb6f1",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770880293,
      "headline": "Earnings Scheduled For February 12, 2026",
      "id": 139055272,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
      "related": "VRTX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=4fd3756cb1814eaf3610e5b762de807b1939a478aa9530d3d91c54b5f01eb6f1"
    }
  }
]